Drug intelligence / Profile preview

EDI-M407

Development stage: Preclinical
Lead developer: Empire Discovery Institute
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

EDI-M407 is a humanized single-domain anti-idiotype antibody developed by the Empire Discovery Institute for the treatment of HER2-positive cancers. Unlike traditional HER2-targeted therapies that bind directly to the HER2 receptor, EDI-M407 is designed to target the idiotype of HER2-directed antibody-drug conjugates (ADCs). This mechanism is intended to enhance the precision and efficacy of ADC delivery or potentially serve as a tool for ADC pharmacokinetic monitoring or neutralization. It is currently in the preclinical stage of development for oncology indications.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on EDI-M407.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDI-M407.

Explore the full profile